Superficial Bladder Cancer Clinical Trial
Official title:
Phase 2b, Multicenter Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
This study is designed to assess the efficacy and safety of DTA-H19/PEI given as six intravesical instillations of 20 mg of plasmid DNA complexed with PEI into the bladder of patients with intermediate risk superficial bladder cancer [recurrent stages Ta (low or high grade)and T1, (low grade) transitional cell carcinoma (TCC)] who have failed prior intravesical therapies including either Bacillus Calmette-Guérin (BCG) or chemotherapy. The primary efficacy objective is to determine the effect of DTA-H19/PEI on the prevention of new tumors after the induction course of 6 weekly intravesical administrations of investigational product assessed 8 to 10 weeks after the start of treatment. Secondary objectives include assessing the ablative effect of DTA-H19/PEI on a marker tumor, safety assessed by the incidence and severity of adverse events, determining the long-term (46 weeks) continued rates of absence of bladder cancer, and time to tumor recurrence in those patients who had a complete response (CR) after the induction course.
DTA-H19, is a doubled stranded DNA plasmid that carries the gene for the diphtheria toxin A (DT-A) chain under the regulation of the H19 promoter sequence. This is a Patient-Oriented, Targeted Therapy as DT-A chain expression is triggered by the presence of H19 transcription factors that are upregulated in tumor cells. The selective initiation of toxin expression results in selective tumor cell destruction via inhibition of protein synthesis in the tumor cell, enabling highly targeted cancer treatment. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01687244 -
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
|
Phase 2 | |
Completed |
NCT02773849 -
ADSTILADRIN (=INSTILADRIN) in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
|
Phase 3 | |
Recruiting |
NCT03379909 -
Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer
|
Phase 2 | |
Completed |
NCT00782587 -
Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer
|
Phase 1 | |
Recruiting |
NCT05084586 -
Comparison of the Efficacy and Safety of Continuous and Single-Dose Intravesical Epirubicin Instillation
|
N/A | |
Recruiting |
NCT03121768 -
A New Prognostic Model for Predicting the Outcome of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
|
N/A | |
Completed |
NCT03091764 -
Evaluation of a Patient-Reported Symptom Index for NMIBC
|
||
Completed |
NCT01939756 -
Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms
|
Phase 1/Phase 2 | |
Completed |
NCT02007005 -
Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01149174 -
Preoperative Intravesical Electromotive Mitomycin-c for Primary Non-muscle Invasive Bladder Cancer
|
Phase 3 | |
Completed |
NCT00322699 -
Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00191711 -
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
|
Phase 2 | |
Completed |
NCT00192049 -
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT04752722 -
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
|
Phase 1/Phase 2 | |
Recruiting |
NCT02106572 -
Therapeutic Instillation of Mistletoe
|
Phase 3 | |
Completed |
NCT00734994 -
Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer
|
Phase 0 |